As of February 1st 2025, Michael Bosshard (pictured) is a new parter at Bratschi’s Basel office. The firm Bratschi is a Swiss full service law firm with seven locations across the country. Its services are
Niederer Kraft Frey advised German biotech & pharma consultant Athagoras on the financing process within the acquisitions of CSO and MigX. The parties involved Athagoras is a technology-enabled platform for life sciences that supports pharma,
Kellerhals Carrard advised Oxyle, a cleantech spinoff company of ETH Zurich, through successful completion of a $16 million seed financing round. 360 Capital led the capital round in question, with additional support from Axeleo Capital, and returning
Walder Wyss advised Danish life science investor Novo Holdings through its acquisition of American pharma multinational Catalent. Globally active in the fields of life sciences and healthcare, Novo Holdings acts as the only asset manager
Schellenberg Wittmer advised German retailer Obi on the takeover its Swiss store line-up from former franchise partner Migros. Following the transaction, Obi Group takes over the entire Swiss store fleet, previously contracted-out to franchise partner
Kellerhals Carrard advised Lausanne-based start-up Voltiris in its seed financing round of CHF 4.8M. Investors EquityPitcher Ventures and 3M Ventures co-led the capital round, with further support from the climate tech venture capital fund
Altenburger advised Dr. med. Hanifa Bouzourene, director of Modern-Path, and Dr. med. Noureddine Bouzourene, through successful completion of a sale operation. The deal Following the transaction, the selling part ceded Modern-Path , a Lausanne-based state of
Bär & Karrer advised Swiss manufacturer United Grinding Groupon a EUR 800 million acquisition and working capital credit facility regarding the financing of the acquisition of the GF Machining Solutions business unit of Georg Fischer.
Niederer Kraft Frey (NKF) advised Swiss company CGS, a full-service provider specialising in the disposal of landmines, Improvised Explosive Devices (IEDs) and other explosive hazards, on the sale of 2,532,055 shares in R&S Group (
Vischer advised Atanis Biotech, a Swiss biotechnology company, to successful completion of an oversubscribed financing round. The financing round The proceeds from this operation will fund the European and North-American marketing campaigns for Atanis’s “
